Open label study to establish the efficacy of intravenous loading doses of Ibandronate 6 mg in patients with lung cancer and skeletal metastased experiencing moderate to severe bone pain.
Phase of Trial: Phase II
Latest Information Update: 31 Oct 2011
At a glance
- Drugs Ibandronic acid (Primary)
- Indications Bone metastases; Non-small cell lung cancer
- Focus Therapeutic Use
- 09 Aug 2011 New trial record